242 related articles for article (PubMed ID: 25140871)
21. Profile and persistence of the virus-specific neutralizing humoral immune response in human survivors of Sudan ebolavirus (Gulu).
Sobarzo A; Groseth A; Dolnik O; Becker S; Lutwama JJ; Perelman E; Yavelsky V; Muhammad M; Kuehne AI; Marks RS; Dye JM; Lobel L
J Infect Dis; 2013 Jul; 208(2):299-309. PubMed ID: 23585686
[TBL] [Abstract][Full Text] [Related]
22. A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates.
Bornholdt ZA; Herbert AS; Mire CE; He S; Cross RW; Wec AZ; Abelson DM; Geisbert JB; James RM; Rahim MN; Zhu W; Borisevich V; Banadyga L; Gunn BM; Agans KN; Wirchnianski AS; Goodwin E; Tierney K; Shestowsky WS; Bohorov O; Bohorova N; Velasco J; Ailor E; Kim D; Pauly MH; Whaley KJ; Alter G; Walker LM; Chandran K; Zeitlin L; Qiu X; Geisbert TW; Dye JM
Cell Host Microbe; 2019 Jan; 25(1):49-58.e5. PubMed ID: 30629918
[TBL] [Abstract][Full Text] [Related]
23. Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodies.
Murin CD; Gilchuk P; Ilinykh PA; Huang K; Kuzmina N; Shen X; Bruhn JF; Bryan AL; Davidson E; Doranz BJ; Williamson LE; Copps J; Alkutkar T; Flyak AI; Bukreyev A; Crowe JE; Ward AB
Cell Rep; 2021 Apr; 35(2):108984. PubMed ID: 33852862
[TBL] [Abstract][Full Text] [Related]
24. Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site.
Howell KA; Qiu X; Brannan JM; Bryan C; Davidson E; Holtsberg FW; Wec AZ; Shulenin S; Biggins JE; Douglas R; Enterlein SG; Turner HL; Pallesen J; Murin CD; He S; Kroeker A; Vu H; Herbert AS; Fusco ML; Nyakatura EK; Lai JR; Keck ZY; Foung SKH; Saphire EO; Zeitlin L; Ward AB; Chandran K; Doranz BJ; Kobinger GP; Dye JM; Aman MJ
Cell Rep; 2016 May; 15(7):1514-1526. PubMed ID: 27160900
[TBL] [Abstract][Full Text] [Related]
25. Potent neutralizing monoclonal antibodies against Ebola virus isolated from vaccinated donors.
Fan P; Chi X; Liu G; Zhang G; Chen Z; Liu Y; Fang T; Li J; Banadyga L; He S; Yu C; Qiu X; Chen W
MAbs; 2020; 12(1):1742457. PubMed ID: 32213108
[TBL] [Abstract][Full Text] [Related]
26. Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection.
Flyak AI; Shen X; Murin CD; Turner HL; David JA; Fusco ML; Lampley R; Kose N; Ilinykh PA; Kuzmina N; Branchizio A; King H; Brown L; Bryan C; Davidson E; Doranz BJ; Slaughter JC; Sapparapu G; Klages C; Ksiazek TG; Saphire EO; Ward AB; Bukreyev A; Crowe JE
Cell; 2016 Jan; 164(3):392-405. PubMed ID: 26806128
[TBL] [Abstract][Full Text] [Related]
27. Longitudinal Human Antibody Repertoire against Complete Viral Proteome from Ebola Virus Survivor Reveals Protective Sites for Vaccine Design.
Khurana S; Ravichandran S; Hahn M; Coyle EM; Stonier SW; Zak SE; Kindrachuk J; Davey RT; Dye JM; Chertow DS
Cell Host Microbe; 2020 Feb; 27(2):262-276.e4. PubMed ID: 32053790
[TBL] [Abstract][Full Text] [Related]
28. Novel Cross-Reactive Monoclonal Antibodies against Ebolavirus Glycoproteins Show Protection in a Murine Challenge Model.
Duehr J; Wohlbold TJ; Oestereich L; Chromikova V; Amanat F; Rajendran M; Gomez-Medina S; Mena I; tenOever BR; García-Sastre A; Basler CF; Munoz-Fontela C; Krammer F
J Virol; 2017 Aug; 91(16):. PubMed ID: 28592526
[TBL] [Abstract][Full Text] [Related]
29. Post-Exposure Protection in Mice against Sudan Virus by a Two Antibody Cocktail.
Froude JW; Herbert AS; Pelat T; Miethe S; Zak SE; Brannan JM; Bakken RR; Steiner AR; Yin G; Hallam TJ; Sato AK; Hust M; Thullier P; Dye JM
Viruses; 2018 May; 10(6):. PubMed ID: 29861435
[TBL] [Abstract][Full Text] [Related]
30. Serological evidence of exposure to ebolaviruses in domestic pigs from Guinea.
Fischer K; Camara A; Troupin C; Fehling SK; Strecker T; Groschup MH; Tordo N; Diederich S
Transbound Emerg Dis; 2020 Mar; 67(2):724-732. PubMed ID: 31627257
[TBL] [Abstract][Full Text] [Related]
31. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.
Wang D; Raja NU; Trubey CM; Juompan LY; Luo M; Woraratanadharm J; Deitz SB; Yu H; Swain BM; Moore KM; Pratt WD; Hart MK; Dong JY
J Virol; 2006 Mar; 80(6):2738-46. PubMed ID: 16501083
[TBL] [Abstract][Full Text] [Related]
32. Pan-Filovirus Serum Neutralizing Antibodies in a Subset of Congolese Ebolavirus Infection Survivors.
Bramble MS; Hoff N; Gilchuk P; Mukadi P; Lu K; Doshi RH; Steffen I; Nicholson BP; Lipson A; Vashist N; Sinai C; Spencer D; Olinger G; Wemakoy EO; Illunga BK; Pettitt J; Logue J; Marchand J; Varughese J; Bennett RS; Jahrling P; Cavet G; Serafini T; Ollmann Saphire E; Vilain E; Muyembe-Tamfum JJ; Hensely LE; Simmons G; Crowe JE; Rimoin AW
J Infect Dis; 2018 Nov; 218(12):1929-1936. PubMed ID: 30107445
[TBL] [Abstract][Full Text] [Related]
33. Interferon α/β Receptor-Deficient Mice as a Model for Ebola Virus Disease.
Brannan JM; Froude JW; Prugar LI; Bakken RR; Zak SE; Daye SP; Wilhelmsen CE; Dye JM
J Infect Dis; 2015 Oct; 212 Suppl 2():S282-94. PubMed ID: 25943199
[TBL] [Abstract][Full Text] [Related]
34. Sudan ebolavirus long recovered survivors produce GP-specific Abs that are of the IgG1 subclass and preferentially bind FcγRI.
Radinsky O; Edri A; Brusilovsky M; Fedida-Metula S; Sobarzo A; Gershoni-Yahalom O; Lutwama J; Dye J; Lobel L; Porgador A
Sci Rep; 2017 Jul; 7(1):6054. PubMed ID: 28729706
[TBL] [Abstract][Full Text] [Related]
35. Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection.
Williamson LE; Flyak AI; Kose N; Bombardi R; Branchizio A; Reddy S; Davidson E; Doranz BJ; Fusco ML; Saphire EO; Halfmann PJ; Kawaoka Y; Piper AE; Glass PJ; Crowe JE
J Virol; 2019 Apr; 93(8):. PubMed ID: 30728263
[TBL] [Abstract][Full Text] [Related]
36. Antibody Repertoires to the Same Ebola Vaccine Antigen Are Differentially Affected by Vaccine Vectors.
Meyer M; Yoshida A; Ramanathan P; Saphire EO; Collins PL; Crowe JE; Samal S; Bukreyev A
Cell Rep; 2018 Aug; 24(7):1816-1829. PubMed ID: 30110638
[TBL] [Abstract][Full Text] [Related]
37. A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques.
Singh K; Marasini B; Chen X; Ding L; Wang JJ; Xiao P; Villinger F; Spearman P
J Virol; 2020 Apr; 94(9):. PubMed ID: 32075939
[TBL] [Abstract][Full Text] [Related]
38. Design and evaluation of bi- and trispecific antibodies targeting multiple filovirus glycoproteins.
Nyakatura EK; Zak SE; Wec AZ; Hofmann D; Shulenin S; Bakken RR; Aman MJ; Chandran K; Dye JM; Lai JR
J Biol Chem; 2018 Apr; 293(16):6201-6211. PubMed ID: 29500195
[TBL] [Abstract][Full Text] [Related]
39. A Novel Bacterium-Like Particle-Based Vaccine Displaying the SUDV Glycoprotein Induces Potent Humoral and Cellular Immune Responses in Mice.
Xu S; Jiao C; Jin H; Li W; Li E; Cao Z; Shi Z; Yan F; Zhang S; He H; Chi H; Feng N; Zhao Y; Gao Y; Yang S; Wang J; Wang H; Xia X
Viruses; 2019 Dec; 11(12):. PubMed ID: 31835785
[TBL] [Abstract][Full Text] [Related]
40. Structural Biology Illuminates Molecular Determinants of Broad Ebolavirus Neutralization by Human Antibodies for Pan-Ebolavirus Therapeutic Development.
Murin CD; Gilchuk P; Crowe JE; Ward AB
Front Immunol; 2021; 12():808047. PubMed ID: 35082794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
